Fig. 4
From: The effects of ARID1A mutation in gastric cancer and its significance for treatment
ARID1A-deficient gastric cancer immunotherapy synergistic targeted therapy strategy. ARID1A, the AT-rich interaction domain 1Â A; PD-L1, programmed cell death ligand 1; TMB, tumor mutation burden; dMMR, different Mismatch Repair; MSI-H, microsatellite instability-high; TILs, Tumor Infiltrating Lymphocytes; PARP, poly (ADP-ribose) polymerase; EZH2, enhancer of zeste homolog 2; GSH, glutathione